Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications

被引:1
|
作者
Sposito, Marco [1 ,2 ]
Eccher, Serena [1 ,2 ]
Pasqualin, Luca [1 ,2 ]
Scaglione, Ilaria Mariangela [1 ,2 ]
Avancini, Alice [1 ,3 ]
Tregnago, Daniela [1 ,2 ]
Trestini, Ilaria [4 ]
Insolda, Jessica [1 ,2 ]
Bonato, Adele [5 ]
Ugel, Stefano [6 ,7 ]
Derosa, Lisa [8 ,9 ]
Milella, Michele [1 ,2 ]
Pilotto, Sara [1 ,2 ]
Belluomini, Lorenzo [1 ,2 ]
机构
[1] Univ Verona Sch Med, Dept Engn Innovat Med DIMI, Sect Oncol, Verona, Italy
[2] Verona Univ Hosp Trust, Verona, Italy
[3] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy
[4] Univ & Hosp Trust AOUI Verona, Hosp Med Direct, Dietet Serv, Verona, Italy
[5] Santa Chiara Hosp, Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[6] Univ Verona, Univ Hosp, Immunol Sect, Verona, Italy
[7] Univ Verona, Dept Med, Verona, Italy
[8] INSERM U1015, Gustave Roussy Canc Campus, Villejuif, France
[9] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France
关键词
Anaplastic lymphoma kinase; immunotherapy; non-small cell lung cancer; targeted therapy; tumor immune microenvironment; CD8(+) T-CELLS; PD-L1; EXPRESSION; PLUS NIVOLUMAB; OPEN-LABEL; IMMUNOTHERAPY; EFFICACY; SAFETY; HETEROGENEITY; CERITINIB; EGFR;
D O I
10.1080/1744666X.2024.2372327
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionApproximately 5% of non-small cell lung cancer (NSCLC), exhibits anaplastic lymphoma kinase (ALK) rearrangements. EML4-ALK fusions account for over 90% of ALK rearrangements in NSCLC. The advent of treatment targeting ALK has significantly improved survival rates in patients with advanced ALK-positive NSCLC. However, the emergence of resistance mechanisms and the subsequent progression disease inevitably occurs. The tumor immune microenvironment (TIME) plays a pivotal role in lung cancer, influencing disease development, patient's outcomes, and response to treatments.Areas coveredThe aim of this review is to provide a comprehensive characterization of the TIME in ALK rearranged NSCLC and its intrinsic plasticity under treatment pressure.Expert opinionRecognizing the fundamental role of the TIME in cancer progression has shifted the paradigm from a tumor cell-centric perspective to the understanding of a complex tumor ecosystem. Understanding the intricate dynamics of the TIME, its influence on treatment response, and the potential of immunotherapy in patients with ALK-positive NSCLC are currently among the primary research objectives in this patient population.
引用
收藏
页码:959 / 970
页数:12
相关论文
共 35 条
  • [31] Pralsetinib in acquired RET fusion-positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: A China multi-center, real-world data (RWD) analysis
    Hu, J.
    Tang, X.
    Guo, R.
    Wang, Y.
    Shen, H.
    Wang, H.
    Yao, Y.
    Cai, X.
    Yu, Z.
    Dong, G.
    Liang, F.
    Cao, J.
    Zeng, L.
    Su, M.
    Kong, W.
    Liu, L.
    Huang, W.
    Cai, C.
    Xie, Y.
    Mao, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S62 - S62
  • [32] Immune microenvironment of small cell lung cancer (SCLC): Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating lymphocytes
    Pavan, A.
    Fassan, M.
    Dieci, M. V.
    Attili, I.
    Pasello, G.
    Calabrese, F.
    Rea, F.
    Rugge, M.
    Conte, P. F.
    Bonanno, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S43 - S43
  • [33] Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine
    Spagnol, Giulia
    Sensi, Francesca
    De Tommasi, Orazio
    Marchetti, Matteo
    Bonaldo, Giulio
    Xhindoli, Livia
    Noventa, Marco
    Agostini, Marco
    Tozzi, Roberto
    Saccardi, Carlo
    CANCERS, 2023, 15 (07)
  • [34] Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report
    Kunimasa, Kei
    Miyazaki, Akito
    Tamiya, Motohiro
    Inoue, Takako
    Kawamura, Takahisa
    Tanaka, Tsunehiro
    Futamura, Shun
    Komuta, Kiyohide
    Nagata, Shigenori
    Honma, Keiichiro
    Ohkawa, Kazuyoshi
    Nishino, Kazumi
    THORACIC CANCER, 2024, 15 (36) : 2570 - 2574
  • [35] Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
    Haratani, K.
    Hayashi, H.
    Tanaka, T.
    Kaneda, H.
    Togashi, Y.
    Sakai, K.
    Hayashi, K.
    Tomida, S.
    Chiba, Y.
    Yonesaka, K.
    Nonagase, Y.
    Takahama, T.
    Tanizaki, J.
    Tanaka, K.
    Yoshida, T.
    Tanimura, K.
    Takeda, M.
    Yoshioka, H.
    Ishida, T.
    Mitsudomi, T.
    Nishio, K.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1532 - 1539